Synthetic pathway activators
AssigneeArsenal Biosciences, Inc.
InventorsLevi Gray-Rupp, Thomas Gardner, Anzhi Yao
Life of this patent
Estimating the term…
Abstract
Provided herein are novel synthetic pathway activators comprising multimerization regions, transmembrane domains, and intracellular signaling domains.
Claims30
A nucleic acid encoding a synthetic pathway activator (SPA) peptide comprising a chimeric polypeptide comprising:
- a. an extracellular domain comprising a CD34 epitope or a CD34 ectodomain;
- b. a lipid anchor or a transmembrane domain;
- c. an intracellular signaling domain, wherein the intracellular signaling domain comprises a type I cytokine receptor superfamily box2 peptide motif comprising VSVVEIEANDKKP (SEQ ID NO:
- 107), and a tyrosine phosphorylation motif comprising YXPQ;
- and
- d. a multimerization region.
A synthetic pathway activator (SPA) peptide comprising a chimeric polypeptide comprising:
- a. an extracellular domain comprising a CD34 epitope or a CD34 ectodomain;
- b. a lipid anchor or a transmembrane domain;
- c. an intracellular signaling domain, wherein the intracellular signaling domain comprises a type I cytokine receptor superfamily box2 peptide motif comprising VSVVEIEANDKKP (SEQ ID NO:
- 107), and a tyrosine phosphorylation motif comprising YXPQ;
- and
- d. a multimerization region.
A pharmaceutical composition comprising the cell or population of cells of 17, and a pharmaceutically acceptable excipient.
A pharmaceutical composition comprising the cell or population of cells of 18, and a pharmaceutically acceptable excipient.
A pharmaceutical composition comprising the cell or population of cells of 19, and a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.